The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women

T.E. Vogelvang; V. Mijatovic; P. Kenemans; J.J. Emeis; J.A. Heijst; M.J. van der Mooren

doi:https://doi.org/10.1016/j.ajog.2005.02.083

The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women

T.E. Vogelvang, V. Mijatovic, P. Kenemans, J.J. Emeis, J.A. Heijst, M.J. van der Mooren

Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	1384-1394
Journal	American Journal of Obstetrics and Gynecology
Volume	193
Issue number	4
DOIs	https://doi.org/10.1016/j.ajog.2005.02.083
Publication status	Published - 2005

Access to Document

https://doi.org/10.1016/j.ajog.2005.02.083

Cite this

Vogelvang, T. E., Mijatovic, V., Kenemans, P., Emeis, J. J., Heijst, J. A., & van der Mooren, M. J. (2005). The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. American Journal of Obstetrics and Gynecology, 193(4), 1384-1394. https://doi.org/10.1016/j.ajog.2005.02.083

Vogelvang, T.E. ; Mijatovic, V. ; Kenemans, P. et al. / The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. In: American Journal of Obstetrics and Gynecology. 2005 ; Vol. 193, No. 4. pp. 1384-1394.

@article{86393fa7a75848cbaf132ff0bc96bb4b,

title = "The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women",

author = "T.E. Vogelvang and V. Mijatovic and P. Kenemans and J.J. Emeis and J.A. Heijst and {van der Mooren}, M.J.",

year = "2005",

doi = "https://doi.org/10.1016/j.ajog.2005.02.083",

language = "English",

volume = "193",

pages = "1384--1394",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "4",

}

Vogelvang, TE, Mijatovic, V , Kenemans, P, Emeis, JJ, Heijst, JA & van der Mooren, MJ 2005, 'The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women', American Journal of Obstetrics and Gynecology, vol. 193, no. 4, pp. 1384-1394. https://doi.org/10.1016/j.ajog.2005.02.083

The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. / Vogelvang, T.E.; Mijatovic, V.; Kenemans, P. et al.
In: American Journal of Obstetrics and Gynecology, Vol. 193, No. 4, 2005, p. 1384-1394.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women

AU - Vogelvang, T.E.

AU - Mijatovic, V.

AU - Kenemans, P.

AU - Emeis, J.J.

AU - Heijst, J.A.

AU - van der Mooren, M.J.

PY - 2005

Y1 - 2005

U2 - https://doi.org/10.1016/j.ajog.2005.02.083

DO - https://doi.org/10.1016/j.ajog.2005.02.083

M3 - Article

SN - 0002-9378

VL - 193

SP - 1384

EP - 1394

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

IS - 4

ER -

Vogelvang TE, Mijatovic V , Kenemans P, Emeis JJ, Heijst JA, van der Mooren MJ. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. American Journal of Obstetrics and Gynecology. 2005;193(4):1384-1394. doi: https://doi.org/10.1016/j.ajog.2005.02.083